Market capitalization | $69.16m |
Enterprise Value | $65.07m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 24.65 |
EV/Sales (TTM) EV/Sales | 0.66 |
P/S ratio (TTM) P/S ratio | 0.70 |
P/B ratio (TTM) P/B ratio | 2.37 |
Revenue growth (TTM) Revenue growth | 22.37% |
Revenue (TTM) Revenue | $98.92m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
3 Analysts have issued a Rockwell Medical, Inc. forecast:
3 Analysts have issued a Rockwell Medical, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 99 99 |
22%
22%
|
|
Gross Profit | 17 17 |
105%
105%
|
|
EBITDA | 2.77 2.77 |
150%
150%
|
EBIT (Operating Income) EBIT | 0.58 0.58 |
107%
107%
|
Net Profit | -1.53 -1.53 |
84%
84%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. Its products include Triferic, CitraPure, RenalPure and SteriLyte. The company was founded by Robert L. Chioini in January 1995 and is headquartered in Hackensack, NJ.
Head office | United States |
CEO | Mark Strobeck |
Employees | 237 |
Founded | 1995 |
Website | www.rockwellmed.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.